{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:06:16Z","timestamp":1768453576340,"version":"3.49.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s10753-018-00954-3","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T02:41:05Z","timestamp":1548988865000},"page":"449-462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1936-320X","authenticated-orcid":false,"given":"Mariana Rodrigues","family":"Davanso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Caliari-Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Eduardo Barra","family":"Couri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimas Tadeu","family":"Covas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Merice","family":"de Oliveira Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falio C\u00e9sar","family":"Voltarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelen Cristina Ribeiro","family":"Malmegrim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Navarro Ueda","family":"Yaochite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"issue":"2","key":"954_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF01225454","volume":"16","author":"W Creutzfeldt","year":"1979","unstructured":"Creutzfeldt, W. 1979. The incretin concept today. Diabetologia 16 (2): 75\u201385.","journal-title":"Diabetologia"},{"issue":"10","key":"954_CR2","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/j.1464-5491.2011.03331.x","volume":"28","author":"SL Ellis","year":"2011","unstructured":"Ellis, S.L., E.G. Moser, J.K. Snell-Bergeon, A.S. Rodionova, R.M. Hazenfield, and S.K. Garg. 2011. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabetic Medicine 28 (10): 1176\u20131181.","journal-title":"Diabetic Medicine"},{"issue":"9548","key":"954_CR3","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker, D.J., and M.A. Nauck. 2006. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (9548): 1696\u20131705.","journal-title":"Lancet"},{"key":"954_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1146\/annurev.med.57.110104.115624","volume":"57","author":"LL Baggio","year":"2006","unstructured":"Baggio, L.L., and D.J. Drucker. 2006. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annual Review of Medicine 57: 265\u2013281.","journal-title":"Annual Review of Medicine"},{"key":"954_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1196\/annals.1447.049","volume":"1150","author":"S Xue","year":"2008","unstructured":"Xue, S., C.H. Wasserfall, M. Parker, T.M. Brusko, S. McGrail, K. McGrail, M. Moore, M. Campbell-Thompson, D.A. Schatz, M.A. Atkinson, and M.J. Haller. 2008. Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Annals of the New York Academy of Sciences 1150: 152\u2013156.","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"5","key":"954_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.2337\/diab.42.5.658","volume":"42","author":"C Orskov","year":"1993","unstructured":"Orskov, C., A. Wettergren, and J.J. Holst. 1993. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42 (5): 658\u2013661.","journal-title":"Diabetes"},{"issue":"3","key":"954_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF00577838","volume":"7","author":"VK Hopsu-Havu","year":"1966","unstructured":"Hopsu-Havu, V.K., and G.G. Glenner. 1966. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 7 (3): 197\u2013201.","journal-title":"Histochemie"},{"issue":"5120","key":"954_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1126\/science.8101391","volume":"261","author":"J Kameoka","year":"1993","unstructured":"Kameoka, J., T. Tanaka, Y. Nojima, S.F. Schlossman, and C. Morimoto. 1993. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261 (5120): 466\u2013469.","journal-title":"Science"},{"issue":"1","key":"954_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/10409239309082572","volume":"28","author":"A Yaron","year":"1993","unstructured":"Yaron, A., and F. Naider. 1993. Proline-dependent structural and biological properties of peptides and proteins. Critical Reviews in Biochemistry and Molecular Biology 28 (1): 31\u201381.","journal-title":"Critical Reviews in Biochemistry and Molecular Biology"},{"key":"954_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0076-6879(94)44004-2","volume":"244","author":"ND Rawlings","year":"1994","unstructured":"Rawlings, N.D., and A.J. Barrett. 1994. Families of serine peptidases. Methods in Enzymology 244: 19\u201361.","journal-title":"Methods in Enzymology"},{"issue":"8","key":"954_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0167-5699(99)01486-3","volume":"20","author":"I Meester De","year":"1999","unstructured":"De Meester, I., S. Korom, J. Van Damme, and S. Scharpe. 1999. CD26, let it cut or cut it down. Immunology Today 20 (8): 367\u2013375.","journal-title":"Immunology Today"},{"key":"954_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12933-015-0294-0","volume":"14","author":"EZ Fisman","year":"2015","unstructured":"Fisman, E.Z., and A. Tenenbaum. 2015. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovascular Diabetology 14: 129.","journal-title":"Cardiovascular Diabetology"},{"key":"954_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s13300-018-0372-x","volume":"9","author":"T Kadowaki","year":"2018","unstructured":"Kadowaki, T., K. Sasaki, M. Ishii, M. Matsukawa, and Y. Ushirogawa. 2018. Efficacy and safety of teneligliptin 40 mg in type 2 diabetes: a pooled analysis of two phase III clinical studies. Diabetes Therapy 9: 623.","journal-title":"Diabetes Therapy"},{"key":"954_CR14","first-page":"163","volume":"8","author":"S Nishio","year":"2015","unstructured":"Nishio, S., M. Abe, and H. Ito. 2015. Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes, Metabolic Syndrome & Obesity 8: 163\u2013171.","journal-title":"Diabetes, Metabolic Syndrome & Obesity"},{"issue":"43","key":"954_CR15","doi-asserted-by":"publisher","first-page":"e5229","DOI":"10.1097\/MD.0000000000005229","volume":"95","author":"FF Li","year":"2016","unstructured":"Li, F.F., L.L. Jiang, R.N. Yan, H.H. Zhu, P.H. Zhou, D.F. Zhang, X.F. Su, J.D. Wu, L. Ye, and J.H. Ma. 2016. Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: a randomized, control, open-labeled trial. Medicine (Baltimore) 95 (43): e5229.","journal-title":"Medicine (Baltimore)"},{"key":"954_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3389\/fimmu.2015.00386","volume":"6","author":"D R\u00f6hrborn","year":"2015","unstructured":"R\u00f6hrborn, D., N. Wronkowitz, and J. Eckel. 2015. DPP4 in diabetes. Frontiers in Immunology 6: 386.","journal-title":"Frontiers in Immunology"},{"issue":"16","key":"954_CR17","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.2165\/11206370-000000000-00000","volume":"70","author":"GM Keating","year":"2010","unstructured":"Keating, G.M. 2010. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 70 (16): 2089\u20132112.","journal-title":"Drugs"},{"issue":"2","key":"954_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2165\/11208160-000000000-00000","volume":"72","author":"LP Yang","year":"2012","unstructured":"Yang, L.P. 2012. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. Drugs 72 (2): 229\u2013248.","journal-title":"Drugs"},{"issue":"13","key":"954_CR19","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2165\/11209570-000000000-00000","volume":"72","author":"ED Deeks","year":"2012","unstructured":"Deeks, E.D. 2012. Linagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 72 (13): 1793\u20131824.","journal-title":"Drugs"},{"issue":"15","key":"954_CR20","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2165\/11205080-000000000-00000","volume":"70","author":"LJ Scott","year":"2010","unstructured":"Scott, L.J. 2010. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 70 (15): 2051\u20132072.","journal-title":"Drugs"},{"issue":"2","key":"954_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13300-013-0045-8","volume":"4","author":"DA Tatosian","year":"2013","unstructured":"Tatosian, D.A., Y. Guo, A.K. Schaeffer, N. Gaibu, S. Popa, A. Stoch, R.B. Langdon, and E.A. Kauh. 2013. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Therapy 4 (2): 431\u2013442.","journal-title":"Diabetes Therapy"},{"issue":"5","key":"954_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.numecd.2016.01.001","volume":"26","author":"G Penno","year":"2016","unstructured":"Penno, G., M. Garofolo, and S. Del Prato. 2016. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutrition, Metabolism, and Cardiovascular Diseases 26 (5): 361\u2013373.","journal-title":"Nutrition, Metabolism, and Cardiovascular Diseases"},{"key":"954_CR23","doi-asserted-by":"crossref","unstructured":"Davis, T.M. 2014. Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes, Obesity & Metabolism16 (10): 891\u2013899.","DOI":"10.1111\/dom.12295"},{"key":"954_CR24","doi-asserted-by":"crossref","unstructured":"Zhang, Z., X. Chen, P. Lu, J. Zhang, Y. Xu, W. He, M. Li, S. Zhang, J. Jia, S. Shao, J. Xie, Y. Yang, and X. Yu. 2017. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovascular Diabetology16 (1): 31.","DOI":"10.1186\/s12933-017-0512-z"},{"issue":"3","key":"954_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/1479164114562411","volume":"12","author":"J Koska","year":"2015","unstructured":"Koska, J., M. Sands, C. Burciu, and P. Reaven. 2015. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Diabetes & Vascular Disease Research 12 (3): 154\u2013163.","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"9","key":"954_CR26","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1210\/jc.2012-1544","volume":"97","author":"A Makdissi","year":"2012","unstructured":"Makdissi, A., H. Ghanim, M. Vora, K. Green, S. Abuaysheh, A. Chaudhuri, S. Dhindsa, and P. Dandona. 2012. Sitagliptin exerts an antinflammatory action. The Journal of Clinical Endocrinology and Metabolism 97 (9): 3333\u20133341.","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"954_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000348756","volume":"3","author":"A Aroor","year":"2013","unstructured":"Aroor, A., S. McKarns, R. Nistala, V. Demarco, M. Gardner, M. Garcia-Touza, et al. 2013. DPP-4 inhibitors as therapeutic modulators of immune cell function and associated cardiovascular and renal insulin resistance in obesity and diabetes. Cardiorenal Medicine 3 (1): 48\u201356.","journal-title":"Cardiorenal Medicine"},{"key":"954_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13098-016-0138-4","volume":"8","author":"J Shirakawa","year":"2016","unstructured":"Shirakawa, J., T. Okuyama, M. Kyohara, E. Yoshida, Y. Togashi, K. Tajima, S. Yamazaki, M. Kaji, M. Koganei, H. Sasaki, and Y. Terauchi. 2016. DPP-4 inhibition improves early mortality, \u03b2 cell function, and adipose tissue inflammation in db\/db mice fed a diet containing sucrose and linoleic acid. Diabetology and Metabolic Syndrome 8: 16.","journal-title":"Diabetology and Metabolic Syndrome"},{"issue":"7","key":"954_CR29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1089\/met.2017.0057","volume":"15","author":"J He","year":"2017","unstructured":"He, J., G. Yuan, F. Cheng, J. Zhang, and X. Guo. 2017. Mast cell and M1 macrophage infiltration and local pro-inflammatory factors were attenuated with incretin-based therapies in obesity-related Glomerulopathy. Metabolic Syndrome and Related Disorders 15 (7): 344\u2013353.","journal-title":"Metabolic Syndrome and Related Disorders"},{"key":"954_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10557-018-6778-x","volume":"32","author":"Y Birnbaum","year":"2018","unstructured":"Birnbaum, Y., M. Bajaj, H.C. Yang, and Y. Ye. 2018. Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3\/ASC Inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes. Cardiovascular Drugs and Therapy 32: 135\u2013145.","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"5","key":"954_CR31","doi-asserted-by":"publisher","first-page":"E876","DOI":"10.1210\/jc.2013-3633","volume":"99","author":"Y Zhao","year":"2014","unstructured":"Zhao, Y., L. Yang, Y. Xiang, L. Liu, G. Huang, Z. Long, X. Li, R.D. Leslie, X. Wang, and Z. Zhou. 2014. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains \u03b2-cell function in patients with recent-onset latent autoimmune diabetes in adults: One year prospective study. The Journal of Clinical Endocrinology and Metabolism 99 (5): E876\u2013E880.","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"954_CR32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0091-6749(97)70248-3","volume":"100","author":"M Willheim","year":"1997","unstructured":"Willheim, M., C. Ebner, K. Baier, W. Kern, K. Schrattbauer, R. Thien, et al. 1997. Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. The Journal of Allergy and Clinical Immunology 100 (3): 348\u2013355.","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"954_CR33","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S0171-2985(97)80084-8","volume":"197","author":"OJ Cordero","year":"1997","unstructured":"Cordero, O.J., F.J. Salgado, J.E. Vinuela, and M. Nogueira. 1997. Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiology 197 (5): 522\u2013533.","journal-title":"Immunobiology"},{"key":"954_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1530\/EDM-16-0099","volume":"2016","author":"MM Pinheiro","year":"2016","unstructured":"Pinheiro, M.M., F.M. Pinheiro, and M.A. Torres. 2016. Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3. Endocrinology Diabetes Metabolism Case Reports 2016: 16\u20130099.","journal-title":"Endocrinology Diabetes Metabolism Case Reports"},{"issue":"11","key":"954_CR35","doi-asserted-by":"publisher","first-page":"e0142186","DOI":"10.1371\/journal.pone.0142186","volume":"10","author":"N Alonso","year":"2015","unstructured":"Alonso, N., M.T. Juli\u00e1n, J. Carrascal, R. Colobran, I. Pujol-Autonell, S. Rodriguez-Fern\u00e1ndez, A. Teniente, M.A. Fern\u00e1ndez, A. Mi\u00f1arro, M.C. Ruiz de Villa, M. Vives-Pi, and M. Puig-Domingo. 2015. Type 1 diabetes prevention in NOD mice by targeting DPPIV\/CD26 is associated with changes in CD8+T effector memory subset. PLoS One 10 (11): e0142186.","journal-title":"PLoS One"},{"issue":"3","key":"954_CR36","first-page":"116","volume":"59","author":"L Vargov\u00e1","year":"2013","unstructured":"Vargov\u00e1, L., K. Zacharovov\u00e1, E. Dovolilov\u00e1, L. Vojtov\u00e1, Z. Cimburek, and F. Saudek. 2013. The effects of DPP-IV inhibition in NOD mice with overt diabetes. Folia Biologica (Praha) 59 (3): 116\u2013122.","journal-title":"Folia Biologica (Praha)"},{"issue":"7","key":"954_CR37","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.2337\/db09-1618","volume":"59","author":"SJ Kim","year":"2010","unstructured":"Kim, S.J., C. Nian, and C.H. McIntosh. 2010. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways. Diabetes 59 (7): 1739\u20131750.","journal-title":"Diabetes"},{"issue":"3","key":"954_CR38","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.bbrc.2013.12.049","volume":"443","author":"R Kodera","year":"2014","unstructured":"Kodera, R., K. Shikata, T. Takatsuka, K. Oda, S. Miyamoto, N. Kajitani, D. Hirota, T. Ono, H.K. Usui, and H. Makino. 2014. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochemical and Biophysical Research Communications 443 (3): 828\u2013833.","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"5","key":"954_CR39","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s13300-017-0299-7","volume":"8","author":"T Awata","year":"2017","unstructured":"Awata, T., A. Shimada, T. Maruyama, Y. Oikawa, N. Yasukawa, S. Kurihara, Y. Miyashita, M. Hatano, Y. Ikegami, M. Matsuda, M. Niwa, Y. Kazama, S. Tanaka, and T. Kobayashi. 2017. Possible Long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S). Diabetes Therapy 8 (5): 1123\u20131134.","journal-title":"Diabetes Therapy"},{"key":"954_CR40","volume":"2014","author":"MM Lima-Mart\u00ednez","year":"2014","unstructured":"Lima-Mart\u00ednez, M.M., E. Guerra-Alcal\u00e1, M. Contreras, J. Nastasi, J.A. Noble, and C. Polychronakos. 2014. One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin. Endocrinology Diabetes Metabolism Case Report 2014: 140072.","journal-title":"Endocrinology Diabetes Metabolism Case Report"},{"issue":"6","key":"954_CR41","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/dom.12453","volume":"17","author":"JE Schopman","year":"2015","unstructured":"Schopman, J.E., J.B. Hoekstra, B.M. Frier, M.T. Ackermans, J.J. de Sonnaville, A.M. Stades, et al. 2015. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study. Diabetes, Obesity & Metabolism 17 (6): 546\u2013553.","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"15","key":"954_CR42","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1001\/jama.2009.470","volume":"301","author":"CE Couri","year":"2009","unstructured":"Couri, C.E., M.C. Oliveira, A.B. Stracieri, D.A. Moraes, F. Pieroni, G.M. Barros, M.I. Madeira, K.C. Malmegrim, M.C. Foss-Freitas, B.P. Sim\u00f5es, E.Z. Martinez, M.C. Foss, R.K. Burt, and J.C. Voltarelli. 2009. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. Journal of the American Medical Association 301 (15): 1573\u20131579.","journal-title":"Journal of the American Medical Association"},{"issue":"11","key":"954_CR43","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/jn\/123.11.1939","volume":"123","author":"PG Reeves","year":"1993","unstructured":"Reeves, P.G., F.H. Nielsen, and G.C. Fahey Jr. 1993. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. The Journal of Nutrition 123 (11): 1939\u20131951.","journal-title":"The Journal of Nutrition"},{"issue":"3","key":"954_CR44","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.imbio.2012.05.010","volume":"218","author":"JN Yaochite","year":"2013","unstructured":"Yaochite, J.N., C. Caliari-Oliveira, M.R. Davanso, D. Carlos, K.C. Malmegrim, C.R. Cardoso, et al. 2013. Dynamic changes of the Th17\/Tc17 and regulatory T cell populations interfere in the experimental autoimmune diabetes pathogenesis. Immunobiology 218 (3): 338\u2013352.","journal-title":"Immunobiology"},{"issue":"3","key":"954_CR45","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1210\/en.2007-1137","volume":"149","author":"I Hadjiyanni","year":"2008","unstructured":"Hadjiyanni, I., L.L. Baggio, P. Poussier, and D.J. Drucker. 2008. Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 149 (3): 1338\u20131349.","journal-title":"Endocrinology"},{"issue":"7","key":"954_CR46","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1210\/en.2010-0068","volume":"151","author":"L Tian","year":"2010","unstructured":"Tian, L., J. Gao, J. Hao, Y. Zhang, H. Yi, T.D. O'Brien, R. Sorenson, J. Luo, and Z. Guo. 2010. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 151 (7): 3049\u20133060.","journal-title":"Endocrinology"},{"issue":"11","key":"954_CR47","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.2337\/db10-0676","volume":"59","author":"HA Keenan","year":"2010","unstructured":"Keenan, H.A., J.K. Sun, J. Levine, A. Doria, L.P. Aiello, G. Eisenbarth, S. Bonner-Weir, and G.L. King. 2010. Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin medalist study. Diabetes 59 (11): 2846\u20132853.","journal-title":"Diabetes"},{"issue":"10","key":"954_CR48","doi-asserted-by":"publisher","first-page":"E234","DOI":"10.1210\/jc.2010-0932","volume":"95","author":"S Perl","year":"2010","unstructured":"Perl, S., J.A. Kushner, B.A. Buchholz, A.K. Meeker, G.M. Stein, M. Hsieh, M. Kirby, S. Pechhold, E.H. Liu, D.M. Harlan, and J.F. Tisdale. 2010. Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. The Journal of Clinical Endocrinology and Metabolism 95 (10): E234\u2013E239.","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"954_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker, D.J. 2006. The biology of incretin hormones. Cell Metabolism 3 (3): 153\u2013165.","journal-title":"Cell Metabolism"},{"issue":"6","key":"954_CR50","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio, L.L., and D.J. Drucker. 2007. Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (6): 2131\u20132157.","journal-title":"Gastroenterology"},{"issue":"9","key":"954_CR51","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.2337\/diabetes.51.9.2677","volume":"51","author":"JA Pospisilik","year":"2002","unstructured":"Pospisilik, J.A., S.G. Stafford, H.U. Demuth, C.H. McIntosh, and R.A. Pederson. 2002. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes 51 (9): 2677\u20132683.","journal-title":"Diabetes"},{"issue":"4","key":"954_CR52","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2337\/diabetes.51.4.943","volume":"51","author":"JA Pospisilik","year":"2002","unstructured":"Pospisilik, J.A., S.G. Stafford, H.U. Demuth, R. Brownsey, W. Parkhouse, D.T. Finegood, C.H.S. McIntosh, and R.A. Pederson. 2002. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32\/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa\/fa) Zucker rats. Diabetes 51 (4): 943\u2013950.","journal-title":"Diabetes"},{"issue":"9","key":"954_CR53","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jdiacomp.2017.05.016","volume":"31","author":"SL Atkin","year":"2017","unstructured":"Atkin, S.L., N. Katsiki, M. Banach, D.P. Mikhailidis, M. Pirro, and A. Sahebkar. 2017. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-\u03b1 concentrations: a systematic review and meta-analysis of controlled trials. Journal of Diabetes and its Complications 31 (9): 1458\u20131464.","journal-title":"Journal of Diabetes and its Complications"},{"key":"954_CR54","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.diabres.2017.02.010","volume":"126","author":"A Hattori","year":"2017","unstructured":"Hattori, A., M. Takemoto, H. Tokuyama, M. Koshizaka, and K. Yokote. 2017. Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 126: 138\u2013143.","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"6","key":"954_CR55","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1210\/en.2004-0015","volume":"145","author":"PL Brubaker","year":"2004","unstructured":"Brubaker, P.L., and D.J. Drucker. 2004. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145 (6): 2653\u20132659.","journal-title":"Endocrinology"},{"issue":"1","key":"954_CR56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1172\/JCI30076","volume":"117","author":"DJ Drucker","year":"2007","unstructured":"Drucker, D.J. 2007. The role of gut hormones in glucose homeostasis. The Journal of Clinical Investigation 117 (1): 24\u201332.","journal-title":"The Journal of Clinical Investigation"},{"issue":"9","key":"954_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107935","volume":"9","author":"L Ding","year":"2014","unstructured":"Ding, L., C.A. Gysemans, G. Stang\u00e9, Y. Heremans, Y. Yuchi, T. Takiishi, H. Korf, M. Chintinne, R.D. Carr, H. Heimberg, D. Pipeleers, and C. Mathieu. 2014. Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice. PLoS One 9 (9): e107935.","journal-title":"PLoS One"},{"issue":"9","key":"954_CR58","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.bbadis.2014.04.013","volume":"1842","author":"A Gon\u00e7alves","year":"2014","unstructured":"Gon\u00e7alves, A., C. Marques, E. Leal, C.F. Ribeiro, F. Reis, A.F. Ambr\u00f3sio, and R. Fernandes. 2014. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochimica et Biophysica Acta 1842 (9): 1454\u20131463.","journal-title":"Biochimica et Biophysica Acta"},{"key":"954_CR59","first-page":"5308582","volume":"2018","author":"Q Wang","year":"2018","unstructured":"Wang, Q., M. Long, H. Qu, R. Shen, R. Zhang, J. Xu, et al. 2018. DPP-4 inhibitors as treatments for type 1 diabetes mellitus: a systematic review and meta-analysis. Journal Diabetes Research 2018: 5308582.","journal-title":"Journal Diabetes Research"},{"issue":"1","key":"954_CR60","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.diabres.2010.10.012","volume":"91","author":"JM Cho","year":"2011","unstructured":"Cho, J.M., H.W. Jang, H. Cheon, Y.T. Jeong, D.H. Kim, Y.M. Lim, S.H. Choi, E.K. Yang, C.Y. Shin, M.H. Son, S.H. Kim, H.J. Kim, and M.S. Lee. 2011. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing \u03b2-cell replication and neogenesis. Diabetes Research and Clinical Practice 91 (1): 72\u201379.","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"3","key":"954_CR61","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2337\/diabetes.52.3.741","volume":"52","author":"JA Pospisilik","year":"2003","unstructured":"Pospisilik, J.A., J. Martin, T. Doty, J.A. Ehses, N. Pamir, F.C. Lynn, S. Piteau, H.U. Demuth, C.H.S. McIntosh, and R.A. Pederson. 2003. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52 (3): 741\u2013750.","journal-title":"Diabetes"},{"issue":"5","key":"954_CR62","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2337\/db07-1639","volume":"57","author":"SJ Kim","year":"2008","unstructured":"Kim, S.J., C. Nian, D.J. Doudet, and C.H. McIntosh. 2008. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes 57 (5): 1331\u20131339.","journal-title":"Diabetes"},{"issue":"3","key":"954_CR63","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/cei.12068","volume":"172","author":"SM Cabrera","year":"2013","unstructured":"Cabrera, S.M., S.C. Colvin, S.A. Tersey, B. Maier, J.L. Nadler, and R.G. Mirmira. 2013. Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes. Clinical and Experimental Immunology 172 (3): 375\u2013382.","journal-title":"Clinical and Experimental Immunology"},{"issue":"6","key":"954_CR64","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2337\/diacare.19.6.580","volume":"19","author":"WO Creutzfeldt","year":"1996","unstructured":"Creutzfeldt, W.O., N. Kleine, B. Willms, C. Orskov, J.J. Holst, and M.A. Nauck. 1996. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19 (6): 580\u2013586.","journal-title":"Diabetes Care"},{"key":"954_CR65","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fphar.2017.00362","volume":"8","author":"W Liu","year":"2017","unstructured":"Liu, W., D.O. Son, H.K. Lau, Y. Zhou, G.J. Prud'homme, T. Jin, et al. 2017. Combined oral administration of GABA and DPP-4 inhibitor prevents Beta cell damage and promotes beta cell regeneration in mice. Frontiers in Pharmacology 8: 362.","journal-title":"Frontiers in Pharmacology"},{"issue":"7","key":"954_CR66","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.2337\/diabetes.50.7.1562","volume":"50","author":"C Tourrel","year":"2001","unstructured":"Tourrel, C., D. Bailb\u00e9, M.J. Meile, M. Kergoat, and B. Portha. 2001. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50 (7): 1562\u20131570.","journal-title":"Diabetes"},{"issue":"1\u20132","key":"954_CR67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0165-5728(98)00100-3","volume":"87","author":"D Reinhold","year":"1998","unstructured":"Reinhold, D., B. Hemmer, B. Gran, I. Born, J. Faust, K. Neubert, H.F. McFarland, R. Martin, and S. Ansorge. 1998. Inhibitors of dipeptidyl peptidase IV\/CD26 suppress activation of human MBP-specific CD4+ T cell clones. Journal of Neuroimmunology 87 (1\u20132): 203\u2013209.","journal-title":"Journal of Neuroimmunology"},{"issue":"2","key":"954_CR68","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1152\/ajpendo.00463.2010","volume":"300","author":"AD Dobrian","year":"2010","unstructured":"Dobrian, A.D., Q. Ma, J.W. Lindsay, K.A. Leone, K. Ma, J. Coben, et al. 2010. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. American Journal of Physiology. Endocrinology and Metabolism 300 (2): E410\u2013E421.","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"issue":"5","key":"954_CR69","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.immuni.2009.04.009","volume":"30","author":"SZ Josefowicz","year":"2009","unstructured":"Josefowicz, S.Z., and A. Rudensky. 2009. Control of regulatory T cell lineage commitment and maintenance. Immunity 30 (5): 616\u2013625.","journal-title":"Immunity"},{"key":"954_CR70","doi-asserted-by":"crossref","unstructured":"Ohnuma, K., M. Uchiyama, T. Yamochi, K. Nishibashi, O. Hosono, N. Takahashi, S. Kina, H. Tanaka, X. Lin, N.H. Dang, and C. Morimoto. 2007. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. The Journal of Biological Chemistry 282 (13): 10117\u201310131.","DOI":"10.1074\/jbc.M609157200"},{"key":"954_CR71","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/0-306-47920-6_20","volume":"524","author":"H Fan","year":"2003","unstructured":"Fan, H., S. Yan, S. Stehling, D. Marguet, D. Schuppaw, and W. Reutter. 2003. Dipeptidyl peptidase IV\/CD26 in T cell activation, cytokine secretion and immunoglobulin production. Advances in Experimental Medicine and Biology 524: 165\u2013174.","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"1","key":"954_CR72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0165-2478(97)02716-8","volume":"58","author":"D Reinhold","year":"1997","unstructured":"Reinhold, D., U. Bank, F. Buhling, M. Tager, I. Born, J. Faust, et al. 1997. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes. Immunology Letters 58 (1): 29\u201335.","journal-title":"Immunology Letters"},{"key":"954_CR73","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/978-1-4757-9613-1_19","volume":"421","author":"D Reinhold","year":"1997","unstructured":"Reinhold, D., T. Kahne, M. Tager, U. Lendeckel, F. Buhling, U. Bank, et al. 1997. The effect of anti-CD26 antibodies on DNA synthesis and cytokine production (IL-2, IL-10 and IFN-gamma) depends on enzymatic activity of DP IV\/CD26. Advances in Experimental Medicine and Biology 421: 149\u2013155.","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"3","key":"954_CR74","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2337\/db08-1101","volume":"58","author":"SJ Kim","year":"2009","unstructured":"Kim, S.J., C. Nian, D.J. Doudet, and C.H. McIntosh. 2009. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 58 (3): 641\u2013651.","journal-title":"Diabetes"},{"issue":"3","key":"954_CR75","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1530\/JOE-11-0479","volume":"214","author":"J Jelsing","year":"2012","unstructured":"Jelsing, J., N. Vrang, S.B. van Witteloostuijn, M. Mark, and T. Klein. 2012. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves \u03b2-cell mass in non-obese diabetic mice. The Journal of Endocrinology 214 (3): 381\u2013387.","journal-title":"The Journal of Endocrinology"},{"issue":"6","key":"954_CR76","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1210\/jc.2012-4288","volume":"98","author":"SA Lee","year":"2013","unstructured":"Lee, S.A., Y.R. Kim, E.J. Yang, E.J. Kwon, S.H. Kim, S.H. Kang, D.B. Park, B.C. Oh, J. Kim, S.T. Heo, G. Koh, and D.H. Lee. 2013. CD26\/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism 98 (6): 2553\u20132561.","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"954_CR77","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.diabres.2015.10.012","volume":"110","author":"Y Aso","year":"2015","unstructured":"Aso, Y., M. Fukushima, M. Sagara, T. Jojima, T. Iijima, K. Suzuki, A. Momobayashi, K. Kasai, and T. Inukai. 2015. Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. Diabetes Research and Clinical Practice 110 (3): 250\u2013256.","journal-title":"Diabetes Research and Clinical Practice"},{"key":"954_CR78","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejps.2016.12.040","volume":"100","author":"MM Pinheiro","year":"2017","unstructured":"Pinheiro, M.M., C.L. Stoppa, C.J. Valduga, C.E. Okuyama, R. Gorj\u00e3o, R.M. Pereira, et al. 2017. Sitagliptin inhibit human lymphocytes proliferation and Th1\/Th17 differentiation in vitro. European Journal of Pharmaceutical Sciences 100: 17\u201324.","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"2","key":"954_CR79","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V","volume":"14","author":"A Rabinovitch","year":"1998","unstructured":"Rabinovitch, A. 1998. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes\/Metabolism Reviews 14 (2): 129\u2013151.","journal-title":"Diabetes\/Metabolism Reviews"},{"issue":"1","key":"954_CR80","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1152\/physrev.00003.2010","volume":"91","author":"TL Belle van","year":"2011","unstructured":"van Belle, T.L., K.T. Coppieters, and M.G. von Herrath. 2011. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiological Reviews 91 (1): 79\u2013118.","journal-title":"Physiological Reviews"},{"issue":"7","key":"954_CR81","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/08820139.2016.1197243","volume":"45","author":"R Baharlou","year":"2016","unstructured":"Baharlou, R., A. Ahmadi-Vasmehjani, M.H. Davami, F. Faraji, M.R. Atashzar, F. Karimipour, A. Sadeghi, M.A. Asadi, and M. Khoubyari. 2016. Elevated levels of T-helper 17-associated cytokines in diabetes type I patients: indicators for following the course of disease. Immunological Investigations 45 (7): 641\u2013651.","journal-title":"Immunological Investigations"},{"issue":"3","key":"954_CR82","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/cei.12735","volume":"183","author":"SM Bellemore","year":"2016","unstructured":"Bellemore, S.M., E. Nikoopour, O. Krougly, E. Lee-Chan, L.A. Fouser, and B. Singh. 2016. Pathogenic T helper type 17 cells contribute to type 1 diabetes independently of interleukin-22. Clinical and Experimental Immunology 183 (3): 380\u2013388.","journal-title":"Clinical and Experimental Immunology"},{"issue":"8","key":"954_CR83","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00125-013-2935-8","volume":"56","author":"G Kuriya","year":"2013","unstructured":"Kuriya, G., T. Uchida, S. Akazawa, M. Kobayashi, K. Nakamura, T. Satoh, I. Horie, E. Kawasaki, H. Yamasaki, L. Yu, Y. Iwakura, H. Sasaki, Y. Nagayama, A. Kawakami, and N. Abiru. 2013. Double deficiency in IL-17 and IFN-\u03b3 signalling significantly suppresses the development of diabetes in the NOD mouse. Diabetologia 56 (8): 1773\u20131780.","journal-title":"Diabetologia"},{"issue":"3","key":"954_CR84","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/cei.12691","volume":"182","author":"SM Bellemore","year":"2015","unstructured":"Bellemore, S.M., E. Nikoopour, J.A. Schwartz, O. Krougly, E. Lee-Chan, and B. Singh. 2015. Preventative role of interleukin-17 producing regulatory T helper type 17 (Treg 17) cells in type 1 diabetes in non-obese diabetic mice. Clinical and Experimental Immunology 182 (3): 261\u2013269.","journal-title":"Clinical and Experimental Immunology"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10753-018-00954-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-018-00954-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-018-00954-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T19:13:19Z","timestamp":1580497999000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10753-018-00954-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["954"],"URL":"https:\/\/doi.org\/10.1007\/s10753-018-00954-3","relation":{},"ISSN":["0360-3997","1573-2576"],"issn-type":[{"value":"0360-3997","type":"print"},{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]},"assertion":[{"value":"1 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}